Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies
Treatment of type 2 diabetes mellitus (T2DM) in older patients is complicated by a variety of factors and requires an individualized approach. Benefits of intensive glycemic control must be weighed against associated risks. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors are newer antihyperglycemic agents that effectively lower glycated hemoglobin levels, with a low risk of hypoglycemia, and have a neutral or beneficial effect on weight. The purpose of this review is to discuss challenges in treating older patients with T2DM, and the efficacy and safety of these newer classes based on clinical trials in older populations.
Journal of Family Practice
Freeman, Jeffrey, "Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies" (2015). PCOM Scholarly Papers. 1633.
This document is currently not available here.